Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
Monika Pobiruchin,
Sylvia Bochum,
Uwe M. Martens,
Meinhard Kieser,
Wendelin Schramm
Affiliations
Monika Pobiruchin
GECKO Institute for Medicine, Informatics and Economics, Heilbronn University, Max-Planck-Str. 39, 74081 Heilbronn, Germany; Corresponding author. Tel.: +49 (0)7131 504 633.
Sylvia Bochum
Cancer Center Heilbronn-Franken, SLK-Hospitals, Am Gesundbrunnen 20-26, 74078 Heilbronn, Germany
Uwe M. Martens
Cancer Center Heilbronn-Franken, SLK-Hospitals, Am Gesundbrunnen 20-26, 74078 Heilbronn, Germany
Meinhard Kieser
Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany
Wendelin Schramm
GECKO Institute for Medicine, Informatics and Economics, Heilbronn University, Max-Planck-Str. 39, 74081 Heilbronn, Germany
Records of female breast cancer patients were selected from a clinical cancer registry and separated into three cohorts according to HER2-status (human epidermal growth factor receptor 2) and treatment with or without Trastuzumab (a humanized monoclonal antibody). Propensity score matching was used to balance the cohorts. Afterwards, documented information about disease events (recurrence of cancer, metastases, remission of local/regional recurrences, remission of metastases and death) found in the dataset was leveraged to calculate the annual transition probabilities for every cohort.
